Cargando…
Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
Evidence for research over the past decade shows that epigenetic regulation mechanisms run through the development and prognosis of tumors. Therefore, small molecular compounds targeting epigenetic regulation have become a research hotspot in the development of cancer therapeutic drugs. According to...
Autores principales: | Wu, Donglu, Qiu, Ye, Jiao, Yunshuang, Qiu, Zhidong, Liu, Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686570/ https://www.ncbi.nlm.nih.gov/pubmed/33262941 http://dx.doi.org/10.3389/fonc.2020.560487 |
Ejemplares similares
-
PROTACs for BRDs proteins in cancer therapy: a review
por: Wang, Chao, et al.
Publicado: (2022) -
Functional Analysis of O-GlcNAcylation in Cancer Metastasis
por: Wu, Donglu, et al.
Publicado: (2020) -
P-TEFb as a target to reactivate latent HIV: Two Brds are now in hand
por: Rice, Andrew P.
Publicado: (2013) -
HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
por: Wang, Jie, et al.
Publicado: (2022) -
Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development
por: Jin, Ye, et al.
Publicado: (2022)